Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Smallpox - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Smallpox - Pipeline Review, H1 2016', provides an overview of the Smallpox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Smallpox - The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects - The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Smallpox Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Smallpox - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Smallpox Overview 8 Therapeutics Development 9 Pipeline Products for Smallpox - Overview 9 Pipeline Products for Smallpox - Comparative Analysis 10 Smallpox - Therapeutics under Development by Companies 11 Smallpox - Therapeutics under Investigation by Universities/Institutes 12 Smallpox - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Smallpox - Products under Development by Companies 15 Smallpox - Products under Investigation by Universities/Institutes 16 Smallpox - Companies Involved in Therapeutics Development 17 Bavarian Nordic A/S 17 CEL-SCI Corporation 18 Chimerix, Inc. 19 EpiVax, Inc. 20 Nanotherapeutics, Inc. 21 SIGA Technologies, Inc. 22 Symphogen A/S 23 Takeda Pharmaceutical Company Limited 24 TapImmune Inc. 25 Tonix Pharmaceuticals Holding Corp. 26 Smallpox - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (plague + small pox) vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 24a - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 brincidofovir - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CEL-1000 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 cidofovir - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 imatinib mesylate - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Monoclonal Antibodies for Infectious Disease - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 nilotinib - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 PL-801 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 SCV-305 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 small pox vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 smallpox vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 smallpox vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Sym-002 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 tecovirimat - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 TPIV-300 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 VIR-002 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Smallpox - Recent Pipeline Updates 61 Smallpox - Dormant Projects 77 Smallpox - Discontinued Products 78 Smallpox - Product Development Milestones 79 Featured News & Press Releases 79 Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 79 Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 79 Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox 80 Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 80 Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 81 May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 81 Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 82 Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 83 Dec 23, 2014: Chimerix Provides Recap of 2014 Events 83 Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 84 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 85 Disclaimer 86
List of Tables
Number of Products under Development for Smallpox, H1 2016 9 Number of Products under Development for Smallpox - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Smallpox - Pipeline by Bavarian Nordic A/S, H1 2016 17 Smallpox - Pipeline by CEL-SCI Corporation, H1 2016 18 Smallpox - Pipeline by Chimerix, Inc., H1 2016 19 Smallpox - Pipeline by EpiVax, Inc., H1 2016 20 Smallpox - Pipeline by Nanotherapeutics, Inc., H1 2016 21 Smallpox - Pipeline by SIGA Technologies, Inc., H1 2016 22 Smallpox - Pipeline by Symphogen A/S, H1 2016 23 Smallpox - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24 Smallpox - Pipeline by TapImmune Inc., H1 2016 25 Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Assessment by Combination Products, H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Smallpox Therapeutics - Recent Pipeline Updates, H1 2016 61 Smallpox - Dormant Projects, H1 2016 77 Smallpox - Discontinued Products, H1 2016 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.